YDESHealthcare · Biotechnology

YDES Stock Forecast: YD Bio Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$4.00

+2.56% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$283.3M

Ticker Nerd rank

3 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

+9.0%

+46.5%

YTD

−67.2%

−80.5%

From 52W high

−82.7%

From 52W low

+110.5%

$23

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

YDES stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores YD Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility

Size

Revisions

Issuance

Momentum

Growth

Accruals

Quality

Value

Volatility (73): The share price has been relatively steady.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

YDES stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on YDES, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YDES appears on the weeks it earns a place.

Performance

YDES vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, YD Bio Ltd. returned −80.5% against +17.5% for the S&P 500, dividends included.

YDES vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

YDES analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

YD Bio Ltd. (YDES) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −32.3×
Price / sales: 555.1×
Price / book: 0.9×
EV / EBITDA: −2.0×

Growth & margins

Revenue growth (YoY): 95.6%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −444.6%
Net margin: −276.6%

Returns & dividend

Return on equity: −42.7%
Return on assets: −25.4%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

YD Bio Ltd. (YDES) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

YD Bio Ltd. has a market value of $283.3M and an enterprise value of $2.7M.
Shares outstanding: 70.8M.
Trailing P/E: −32.3×.
YD Bio Ltd. employs 0 people.

market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

YDES vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
YDESYD Bio Ltd.	$283.3M	3
FULCFulcrum Therapeutics, Inc.	$289.9M	36
STROSutro Biopharma, Inc.	$276.3M	73
IMRXImmuneering Corp.	$275.7M	47
LYELLyell Immunopharma, Inc.	$293.1M	63
ACIUAC Immune SA	$273.1M	35
FATEFate Therapeutics, Inc.	$268.6M	94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own YD Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest YDES news & analysis

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

GlobeNewsWire · 31 Aug 2026neutral

YD Bio Limited, a Nasdaq-listed biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced its unaudited financial results for the six months ended June 30, 2026. The announcement was made via GlobeNewsWire on August 31, 2026.

Why it matters — A YDES watcher would look to this interim financial disclosure for an update on the company's performance and fiscal standing during the first half of 2026.

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

GlobeNewsWire · 25 Aug 2026positive

YD Bio announced the publication of a peer-reviewed review article in the journal Nutrients, titled "Beyond Bone Health: Exploring the 'Heart–Brain–Bone' Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2)." The article was co-authored by members of the Company's scientific team together with physicians from the Taiwan Chronic Disease Healthcare Association, the Future Health Institute, and Taipei Medical University Hospital, among others.

Why it matters — This peer-reviewed publication lends scientific visibility and external credibility to YD Bio's research collaborations, which YDES watchers would view as a notable achievement for the company's profile.

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

GlobeNewsWire · 28 July 2026positive

YD Bio launched a six-month pilot collaboration with Numia Health to evaluate bringing its blood-based OkaiDx cancer tests to patients in British Columbia, Canada through a cross-border clinical workflow involving mobile blood collection and testing at a US laboratory.

Why it matters — The pilot represents a step toward expanding YD Bio's molecular diagnostics into the Canadian market and testing the scalability of its cross-border testing model.

FAQ

Frequently asked questions about YDES stock

How does Ticker Nerd's model rank YDES?

As at 12 Sept 2026, YD Bio Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (73 of 100).

What is the YDES stock forecast for 2030?

No analyst covering YD Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YDES are extrapolating price history, which says nothing about the business.

How has YDES stock performed over the past year?

YD Bio Ltd. returned -80.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does YD Bio Ltd. do?

What is the latest news on YDES?

The most recent item we track (GlobeNewsWire, 31 Aug 2026): "YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026". YD Bio Limited, a Nasdaq-listed biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced its unaudited financial results for the six months ended June 30, 2026. The announcement was made via GlobeNewsWire on August 31, 2026.

Company

About YD Bio Ltd.

YD Bio Limited is a biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Its current portfolio includes DNA methylation-based cancer detection programs, ophthalmologic products, stem cell- and exosome-based therapeutics, and clinical trial drug supply services. The company also works in blood-based oncology testing, early cancer detection, treatment monitoring, and recurrence tracking, while serving pharmaceutical and biotechnology partners with compliant distribution and clinical trial support. Based in Taipei, Taiwan, YD Bio Limited operates as an integrated healthcare platform spanning diagnostics, regenerative medicine, eye care, and related commercial healthcare markets.

CEO Dr. Ethan Shen Ph.D. · Taiwan · https://www.ydesgroup.com